The SURF trial: Optimizing Surgical excision Using Real-time Fluorescence imaging with indocyanine green

Condition studied

Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)

Investigational medicinal product(s)

Every trial of Indocyanine Green across our registers →

Eligibility

Primary endpoint

Tumor-to-background ratio (TBR) ≥ 1.5 on ex vivo imaging of resected specimens., Proportion of patients with histologically confirmed clear surgical margins (≥1 mm) in fluorescent vs. non-fluorescent areas

Endpoint detail

Concordance between fluorescence signal and histopathology at wound bed and specimen, Number of additional fluorescent lesions biopsied and confirmed as tumor, as well as the number of false-positive and false-negative lesions, Mean fluorescence intensity (MFI) in metastatic vs. non-metastatic lymph nodes, Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), Concordance of ICG fluorescence with complementary imaging or spectroscopy signals, clinical findings, and histopathological outcomes.